舒利迭治疗慢性阻塞性肺疾病疗效观察  

Clinical observation of Seretide on chronic obstructive pulmonary disease

作　　者：李美朝[1] 陈航[2] 刘川[1] 

机构地区：[1]河北省保定市第五医院,河北保定071000 [2]河北大学附属医院,河北保定071000

出　　处：《现代中西医结合杂志》2008年第19期2930-2931,共2页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的观察舒利迭对稳定期（Ⅲ～Ⅳ级）慢性阻塞性肺疾病（COPD）患者肺功能的影响。方法将明确诊断的120例COPD患者随机分为试验组和对照组，2组患者的基础治疗相同，在此基础上，实验组吸入舒利迭，剂型为50μg／250μg，1吸／次，2次／d，疗程3个月；对照组吸入辅舒酮（丙酸氟替卡松）加万托林。辅舒酮1吸／次，2次／d，万托林1吸／次，4次／d，疗程3个月。疗程结束前后进行肺功能检查。结果2组患者在治疗前后肺通气均有改善，其中试验组COPD患者的肺通气功能FEV1、FEV1／FVC、FEV1／预计值％较B组改善更加显著。结论舒利迭可以改善稳定期COPD患者的肺功能，可作为稳定期COPD长期治疗的一线药物。Objective It is to observe the effects of Seretide on lung function of the patients with chronic obstructive pulmonary disease （COPD） in stable stage（Ⅲ～Ⅳ degree）. Methods 120 diagnosed patients were randomly divided into experimental group and control group. Baseline treatments were similar in all patients. In experimental group, twice daily 50/250 〉g dosage form of Seretide were additionally given to the patients for three month. In control group, inhale flixotide and albuterol aerosol. Flixotide was one dosage once a time, twice a day, Albuterol aerosol was one dosage once a time, four times a day. The treatment course was three month. Before and after treatment, lung function of the two groups were examined and compared respectively, Results Lung function（FEV1 ,FEVI/FVC,FEV1% ）of the two groups were all improved, and the improvement of the experiment group was much greater than that in control group. Conclusion Seretide can improve lung function of the patients with COPD in stable stage, and it could be use as a ordinary medicine on the patients for long time.

关 键 词：舒利迭 慢性阻塞性肺疾病 肺功能 

分 类 号：R563[医药卫生—呼吸系统]